15.72
3.42%
+0.52
Neogenomics Inc. stock is currently priced at $15.72, with a 24-hour trading volume of 654.16K.
It has seen a +3.42% increased in the last 24 hours and a +1.03% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $15.30 pivot point. If it approaches the $15.77 resistance level, significant changes may occur.
Neogenomics Inc. Stock (NEO) Financials Data
Neogenomics Inc. (NEO) Revenue 2023
NEO reported a revenue (TTM) of $591.64 million for the quarter ending December 31, 2023, a +16.07% rise year-over-year.
Neogenomics Inc. (NEO) Net Income 2023
NEO net income (TTM) was -$87.97 million for the quarter ending December 31, 2023, a +39.02% increase year-over-year.
Neogenomics Inc. (NEO) Cash Flow 2023
NEO recorded a free cash flow (TTM) of -$30.70 million for the quarter ending December 31, 2023, a +68.31% increase year-over-year.
Neogenomics Inc. (NEO) Earnings per Share 2023
NEO earnings per share (TTM) was -$0.70 for the quarter ending December 31, 2023, a +39.66% growth year-over-year.
Neogenomics Inc. Stock (NEO) Latest News
All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy
Zacks Investment Research
Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?
Zacks Investment Research
What 6 Analyst Ratings Have To Say About NeoGenomics
Benzinga
China’s grip on rare earth elements is slipping. Investors should take note.
MarketWatch
China’s grip on rare earth elements is slipping. Investors should take note.
MarketWatch
Wall Street Analysts Predict a 29.57% Upside in NeoGenomics (NEO): Here's What You Should Know
Zacks Investment Research
About Neogenomics Inc.
NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. The company has a strategic alliance with Pharmaceutical Product Development Inc. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Cap:
|
Volume (24h):